# A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

> **NCT02173301** · PHASE2 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 200 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** XP23829 400 mg QD
- **DRUG:** XP 23829 800 mg QD
- **DRUG:** XP23829 400 mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02173301
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-08
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173301, "A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02173301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*